SCHEMBL4596097

SCHEMBL4596097

O=C1C(=O)N(Cc2cccc3ccccc23)c2ccccc21

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 2/20 0.58
CES1 P23141 7/20 0.58
ALDH1A1 P00352 4/20 0.58
CHRM1 P11229 2/20 0.58
ALDH3A1 P30838 2/20 0.58
ALDH2 P05091 1/20 0.58
BCHE P06276 4/20 0.56
ACHE P22303 2/20 0.55
CES2 O00748 1/20 0.54
CHRM5 P08912 2/20 0.52
CHRM3 P20309 1/20 0.52
CA12 O43570 1/20 0.51
APAF1 O14727 1/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
MAPT P10636 1/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30132795 1.00 TGM2 (0.58) TGM2CES1ALDH1A1CHRM1ALDH3A1
SCHEMBL1337353 0.82 CA12 (0.57) ALDH1A1CA12MAPTPOLBHPGD
SCHEMBL18955151 0.81 CA1 (0.71) CA12
SCHEMBL18954691 0.80 TGM2 (0.68) TGM2CES1ALDH1A1CHRM1ALDH3A1
SCHEMBL5426500 0.79 TGM2 (0.52) TGM2CES1ALDH1A1CHRM1ALDH3A1
SCHEMBL18974754 0.78 TGM2 (0.61) TGM2CES1ALDH1A1CHRM1ALDH3A1
SCHEMBL5430327 0.78 CHRM1 (0.63) TGM2CES1ALDH1A1CHRM1ALDH3A1
SCHEMBL18954909 0.78 ALDH1A1 (0.71) TGM2CES1ALDH1A1CHRM1ALDH3A1
SCHEMBL15928248 0.78 TGM2 (0.75) TGM2CES1ALDH1A1CHRM1ALDH3A1
SCHEMBL4596020 0.78 TGM2 (0.61) TGM2CES1ALDH1A1CHRM1ALDH3A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234938-A1 NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS RHIZEN PHARMACEUTICALS AG (CH) 2023-07-27 US disclosed
CN-115485271-A Novel compounds as inhibitors of poly (ADP-ribose) polymerase (PARP) 理森制药股份公司 2022-12-16 CN disclosed
WO-2017099695-A1 N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS ISTANBUL UNIVERSITESI REKTORLUGU (TR) 2017-06-15 WO disclosed
WO-2017099695-A1 N-[(AMINOSULFONYL)PHENYL]-2-(1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)-HYDRAZINECARBOTHIOAMIDE DERIVATIVES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS ISTANBUL UNIVERSITESI REKTORLUGU (TR) 2017-06-15 WO disclosed
WO-2008046083-A2 USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-04-17 WO disclosed
EP-1877378-A2 OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-01-16 EP disclosed
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2007-05-10 US disclosed
WO-2006113864-A2 OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents OPRL1, OPRK1, TRPV1 TGM2 4700/4885CES1 4183/4885ALDH1A1 1136/4885
US-20230234938-A1 NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS PARP1, PARP2, PARP3 TGM2 605/4885CES1 498/4885ALDH1A1 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.